Activation of naive peripheral T cells by their cognate antigen results in induction of their proliferation and differentiation into T effector cells. These comprise CD4 ϩ T-helper cells and CD8 ϩ cytotoxic T cells, which in turn can induce immune responses by the secretion of cytokines, cell-cell interactions, or their ability to directly kill target cells. Importantly, despite high expression of death receptors such as CD95, effector T cells display an antiapoptotic phenotype allowing immune defense function and clearance of invading antigens. 1,2 Once the infection has been efficiently contained, these T cells become apoptosis-sensitive, leading to deletion of most cells and survival of a few memory T cells. 3, 4 Apoptosis thus represents a tightly regulated process by which lymphocyte homeostasis is controlled and the emergence of autoreactive cells is prevented.
Introduction
Activation of naive peripheral T cells by their cognate antigen results in induction of their proliferation and differentiation into T effector cells. These comprise CD4 ϩ T-helper cells and CD8 ϩ cytotoxic T cells, which in turn can induce immune responses by the secretion of cytokines, cell-cell interactions, or their ability to directly kill target cells. Importantly, despite high expression of death receptors such as CD95, effector T cells display an antiapoptotic phenotype allowing immune defense function and clearance of invading antigens. 1,2 Once the infection has been efficiently contained, these T cells become apoptosis-sensitive, leading to deletion of most cells and survival of a few memory T cells. 3, 4 Apoptosis thus represents a tightly regulated process by which lymphocyte homeostasis is controlled and the emergence of autoreactive cells is prevented.
Upon activation, T cells show a rapid up-regulation of antiapoptotic proteins. In addition to Bcl-x L , a strong increase in FLICEinhibitory proteins (FLIPs) is most prominent. [5] [6] [7] FLIPs inhibit death-receptor-mediated apoptosis by preventing the cleavage of death-inducing signaling complex (DISC)-associated procaspase-8 and Ϫ10 to the mature active enzymes, thereby blocking initiation of the extrinsic apoptosis cascade. 2, 8 Three different isoforms of the cellular FLIP (c-FLIP) have been reported so far, namely c-FLIP long , c-FLIP short , and c-FLIP R , which are generated by alternative splicing. 2, 5, 9 All 3 isoforms comprise a tandem death effector motif (DED) that is crucial for their recruitment into the DISC. 10 Additionally, c-FLIP long contains an inactive caspase-like domain, whereas each of the 2 short isoforms, c-FLIP short and c-FLIP R , possesses a unique truncated C-terminus. For the latter ones only antiapoptotic functions have been described so far, whereas the role of c-FLIP L remains controversial. Next to its antiapoptotic abilities, low levels of c-FLIP long have also been shown to promote cell death by increasing the enzymatic activity of caspase-8. [11] [12] [13] In vitro studies with primary human T cells have shown that FLIP proteins, especially c-FLIP short , are highly up-regulated upon T-cell activation, which correlates with a protection against CD95-mediated apoptosis. 7, 14 Conversely, treatment of activated T cells with the protein translation inhibitor cycloheximide reduced c-FLIP expression, without affecting Bcl-x L expression, and rendered the cells apoptosis sensitive. 7 Therefore, c-FLIP proteins are thought to play a central role in the protection of activated T cells.
How c-FLIP expression in T cells is regulated at the molecular level is a matter of active debate. Inducible c-FLIP expression in peripheral T cells has primarily been linked to the nuclear factor-B (NF-B) signaling pathway [15] [16] [17] [18] ; however, other transcription factor-binding sites do exist in the FLIP promoter. In addition, studies in various tumor cell lines have indicated a regulation of c-FLIP expression by the PI3K/Akt and Erk/MAP kinase pathway. 19 To elucidate the regulation of c-FLIP expression in T lymphocytes, we investigated several signaling pathways for their involvement in activation-induced up-regulation of c-FLIP. Surprisingly, we found that c-FLIP proteins, and especially c-FLIP short expression, were mainly regulated via the calcineurin/nuclear factor of activated T cells (NFAT) pathway. Analysis of the human c-FLIP promoter revealed 3 putative NFAT binding sites in front of exon 1, of which 2 are actively used in T cells for induction of c-FLIP expression. Furthermore, down-regulation of c-FLIP expression by RNA interference or the calcineurin inhibitors cyclosporine A or FK506 sensitized T cells to apoptosis, supporting a central role of NFAT-mediated c-FLIP expression for the protection of activated T cells.
Methods

Cell culture and stable transfections
Approval for these studies was obtained from the institutional review board of Heinrich-Heine-University Düsseldorf's medical faculty. Informed consent was obtained in accordance with the Declaration of Helsinki.
The human T-cell lines HuT78 and CEM were cultured in RPMI 1640 (PAA Laboratories, Cölbe, Germany) supplemented with 10% fetal calf serum (BioWest, Frickenhausen, Germany) and 50 g/mL each of penicillin and streptomycin (Invitrogen, Karlsruhe, Germany). Human embryonic kidney cells (293T) were cultured in Dulbecco modified Eagle medium (DMEM high glucose; PAA Laboratories) supplemented with 10% fetal calf serum and 50 g/mL each of penicillin and streptomycin. HeLa human cervix carcinoma cells were cultured in RPMI 1640 supplemented with 10% fetal calf serum, 2 mM glutamine, 50 M ␤-mercaptoethanol, and 50 g/mL each of penicillin and streptomycin.
Preparation and activation of human peripheral T cells
Human peripheral T cells were isolated by Ficoll-Hypaque density gradient centrifugation (Biochrom, Berlin, Germany) from buffy coat material obtained from the Institute of Hemostasis and Transfusion Medicine of the University Hospital Düsseldorf. Monocytes were depleted by incubation of peripheral blood lymphocytes (PBLs) for 1 hour in RPMI 1640 medium supplemented with 10% fetal calf serum and 50 g/mL each of penicillin and streptomycin in 175-cm 2 cell culture flasks. Nonadherent cells were collected and B lymphocytes were removed by magnetic-activated cell sorting (MACS) via CD20 ϩ MACS beads (Miltenyi Biotec, Bergisch Gladbach, Germany). Purified T lymphocytes were incubated with 5 g/mL Leucoagglutinin (PHA-L) (Sigma, Deisenhofen, Germany) overnight if not stated otherwise. For further cultivation for up to 6 days, T cells were washed 3 times in phosphate-buffered saline (PBS) and supplemented with 25 U/mL interleukin-2 (IL-2; Tebu-bio, Offenbach, Germany). The following signaling pathways inhibitors were used: PD098059 (Sigma), SB203580 (Sigma), JNK-II (Calbiochem, Darmstadt, Germany), cyclosporine A (Calbiochem), FK506 (Alexis, Gruenberg, Germany), rocaglamide (Alexis), and VIVIT peptide. 20 VIVIT peptide was synthesized in-house by standard solid-phase methods, purified by high-performance liquid chromatography (HPLC), and analyzed by mass spectrometry for purity and correct molecular composition.
Transient transfections and luciferase assays
Transient transfection of 293T cells was performed with Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocols. For luciferase assays, 4 g of a pGL3 reporter construct containing nucleotides Ϫ501 to ϩ104 relative to the proposed transcriptional start site of CFLAR (c-FLIP) exon 1 were cotransfected with 0.4 g of a control reporter construct containing the Rous sarcoma virus promoter in front the ␤-galactosidase (lacZ) gene. The c-FLIP promoter construct was kindly provided by Dr Wafik El-Deiry (Philadelphia, PA). 21 In addition to the luciferase constructs, 2 g of an NFATc1 or NFATc2 plasmid were cotransfected with 2 g of a plasmid encoding a constitutively active form of calcineurin. The plasmids encoding NFATc1, NFATc2, and calcineurin were a kind gift of Dr Edgar Serfling (Würzburg, Germany). After a 24-hour transfection, cells were lysed in 100 L of 25 mM glycylglycine/pH 7.8, 15 mM MgSO 4 , 4 mM EGTA, 1 mM dithiothreitol, and 1% Triton X-100 and were centrifuged at 20 000g at 4°C for 5 minutes. Then, 100 L reaction buffer (25 mM glycylglycine/pH 7.8, 15 mM MgSO 4 , 4 mM EGTA, 1 mM dithiothreitol, 2 mM ATP, 15 mM potassium phosphate, pH 7.8) was added to 30 L supernatant and luciferase activity was measured after injection of 100 L luciferin (0.3 mg/mL) using a microplate luminometer (Berthold Technologies, Bad Wildbad, Germany). For normalization, ␤-galactosidase assay was performed using the Galacto Light system (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. FLIP promoter mutants were generated by using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and verified by DNA sequencing.
Lentiviral infection of cells
c-FLIP MISSION TRC shRNA Target Set cloned into the lentiviral vector pLKO.1 was purchased from Sigma. c-FLIP short shRNA oligonucleotides (see Document S1, available on the Blood website; see the Supplemental Materials link at the top of the online article) were annealed and cloned into the lentiviral vector pLKO.1. Lentiviral vectors were cotransfected with the envelope vector pMD2.G (Addgene no. 12259) and the gag-pol expression plasmid pCMV_dR8.2dvpr (Addgene no. 8455) into 293T cells as described in "Transcient transfections and luciferase assays." Lentiviruses (LVs) were harvested 36 hours and 60 hours after transfection. Crude virus was filtered through 0.45-m PVDF filters (Millipore, Billerica, MA), concentrated by ultracentrifugation at 100 000g for 60 minutes at 4°C and stored at Ϫ80°C until further use. Titers were determined by infection of HeLa cells with serial dilutions of LV stocks and 5 g/L polybrene (Sigma). Specific knockdown of the various c-FLIP isoforms was verified by Western blot analysis. CEM cells were infected by adding LVs and 5 g/L polybrene to 2 ϫ 10 6 cells. Cells were centrifuged for 1 hour at 860g and then incubated overnight. At 48 hours after infection, cells were cultured for 2 weeks in selection medium containing 2 g/mL puromycin (Sigma). Successful integration of LVs was confirmed by Western blot analysis.
RNA isolation, RT-PCR, and quantitative real-time PCR
Total RNA was isolated from 5 ϫ 10 6 to 10 ϫ 10 6 cells with the RNeasy kit (Qiagen, Hilden, Germany). Total mRNA (1 g) was used for cDNA synthesis using the SuperScript III First-Strand reverse transcriptasepolymerase chain reaction (RT-PCR) kit of Invitrogen. Real-time PCR was carried out on an Applied Biosystems 7300 Real-Time PCR system using the QuantiTect SYBR Green RT-PCR Kit (Qiagen) according to the manufacturer's instructions. Measurements were run in triplicate and normalized to GAPDH values.
FACS assays
Cell-surface staining and cytotoxicity assays were performed as described previously. 7 For assaying apoptosis, 5 ϫ 10 5 cells were stimulated for 16 hours in 24-well plates (if not stated otherwise) with CD95L, or left untreated for the indicated times. CD69, CD25, and CD3 antibodies used for cell-surface staining were purchased from BD Biosciences (Heidelberg, Germany). CD95 surface staining was performed with 2R2 antibody, which was purified and FITC-conjugated in house. For blocking activationinduced apoptosis, neutralizing anti-CD95L (clone 5G51; BioCheck, Mün-ster, Germany) was added at 5 g/mL to cell cultures. Specific apoptosis was calculated as follows: (% experimental apoptosis Ϫ % spontaneous apoptosis) / (100 Ϫ % spontaneous apoptosis) ϫ 100.
Western blot analysis
Western blot analysis was performed as described previously. 10 Quantification of protein expression was carried out using a LAS 3000 CCD camera (Fujifilm, Düsseldorf, Germany) and AIDA software (Raytest, Sprockhövel, Germany).
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) using nuclear extracts of primary peripheral T lymphocytes or HuT78 cells was performed according to standard procedures. A detailed protocol can be found in the supplementary information.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using a ChIP kit from Upstate Biotechnology (Lake Placid, NY). For each precipitation For personal use only. on January 21, 2018. by guest www.bloodjournal.org From
Results
We have previously reported that primary T cells up-regulate c-FLIP short after 1 day of T-cell receptor (TCR) stimulation. 7, 14 For a more detailed analysis, we stimulated freshly isolated primary human T cells (d0) with the lectin PHA or anti-CD3⑀ antibodies overnight to trigger TCR activation and analyzed the cells directly (d1) or after culture for an additional 2 days (d3) or 5 days (d6) with IL-2. IL-2 was added because of its role as a survival and growth factor as well as its ability to sensitize T cells for activationinduced cell death. 14 Both PHA and anti-CD3⑀ strongly induced the expression of c-FLIP short , which was absent in freshly isolated T cells ( Figure 1A ). Importantly, induction of c-FLIP short expression was only transient and declined upon longer cultivation. In contrast, expression of c-FLIP long and Bcl-x L was detectable under all culture conditions and was only slightly up-regulated on day 1 ( Figure 1A ). The expression of XIAP and Bcl-2, 2 other antiapoptotic proteins, and the MAP kinase (MAPK) Erk2 remained unchanged in the course of T-cell activation ( Figure 1A) .
To investigate the mechanism of c-FLIP short up-regulation, we first used pharmacologic inhibitors of several signaling pathways. Inhibition of the 3 classic MAPK pathways (Erk, p38 MAPK , and JNK) by PD098059, SB203580, and JNK-II, respectively, had no effect on c-FLIP short expression ( Figure 1B ). Even when used at higher micromolar concentrations, c-FLIP expression remained unaffected by MAPK inhibitors ( Figure S1A ). Similarly, the inhibitors wortmannin (PI3K), rapamycin (mTOR), and SB415286 (GSK3) also showed no effect ( Figure S1B ). However, expression of c-FLIP short was significantly reduced in d1 T cells treated with the immunosuppressant cyclosporine A (CsA; Figure 1B ). Interestingly, CsA had only a minor effect on the expression of c-FLIP long , which was similar to that observed in d0 T cells. Of note, CsA reduced but did not abolish T-cell activation, as determined by the expression of the activation markers CD25 and CD69 on the surface of d1 T cells ( Figure 1C ). In contrast, the cdk2 inhibitor roscovitine suppressed c-FLIP up-regulation most likely by a complete inhibition of T-cell activation ( Figure S1B , data not shown). Therefore, we conclude that a CsA-sensitive pathway mediates induction of c-FLIP short .
CsA inhibits the phosphatase calcineurin, which dephosphorylates and thereby activates transcription factors of the NFAT family. 22 As NFAT plays a major role in T-cell biology, we wanted to confirm that CsA inhibits c-FLIP expression by interfering with calcineurin-mediated NFAT activation. Therefore, we used additional inhibitors of the NFAT pathway, such as FK506, 23, 24 rocaglamide, 25 and VIVIT peptide, which blocks calcineurin-NFAT interaction. 20 As shown in Figure 2A , FK506 and the VIVIT peptide inhibited up-regulation of c-FLIP short to an extent similar to CsA, whereas c-FLIP long expression was again only marginally affected. Interestingly, rocaglamide strongly reduced expression of both c-FLIP isoforms, which might be explained by its ability to inhibit both NFAT and NF-B. 26 Taken together, the potent induction of c-FLIP short in T cells relies strongly on the calcineurin/ NFAT pathway.
We then performed quantitative Western blot analysis to determine the extent to which the calcineurin/NFAT pathway contributes to c-FLIP short induction. Upon T-cell activation, c- As a first step, we used the gene2promoter software (Genomatix, Munich, Germany) to determine possible promoter sequences within this chromosomal region. The analysis suggested 2 potential promoter regions, one directly upstream of exon 1 comprising part of the 5Ј UTR and another adjacent to exon 3 containing the start codon ( Figure 3A) . We then analyzed the 2 potential promoters using the MatInspektor (Genomatix) software for the prediction of potential NFAT-binding sites. 27 The first promoter region upstream of exon 1 comprises 3 potential NFAT-binding sites ( Figure 3B ), whereas in the second putative promoter no NFAT-binding sites could be identified (data not shown). Notably, the first promoter also contained one NF-B site ( Figure 3B ), which may explain the NF-B-dependent expression of c-FLIP in certain cell types.
To investigate whether T-cell activation induces binding of NFAT to these putative sites in the c-FLIP promoter region 1, we performed electrophoretic mobility shift assays (EMSAs) using nuclear extracts of the human T-cell line HuT78. Similar to primary T cells, activation of HuT78 cells by Phorbol 12-myristate 13-acetate (PMA) and ionomycin triggered a strong up-regulation of c-FLIP short that was efficiently blocked by CsA ( Figure 4A ). For EMSAs, oligonucleotides were used comprising 1 of the 3 potential binding sites in promoter region 1, termed sites 1, 2, and 3 ( Figure  3B ). T-cell activation rapidly induced DNA-binding activity to site 1 and 2 probes ( Figure 4B ), but not to an oligonucleotide comprising the binding site 3 (data not shown). Interestingly, binding to the first putative NFAT site occurred more rapidly with the strongest shift after 1 hour, whereas DNA binding to the second site was slightly delayed, peaking after 2 hours of cell activation. Binding to the radioactive NFAT consensus oligonucleotide was efficiently competed by an excess of unlabeled site 1 or site 2 oligonucleotides, resulting in a concentration-dependent decrease of the shifted complex, whereas unlabeled site 1 or site 2 probes For personal use only. on January 21, 2018. by guest www.bloodjournal.org From mutated in the NFAT recognition sequence had no effect on protein-DNA complex formation ( Figure 4C ).
In order to determine which of the NFAT proteins bind to the FLIP promoter, we performed supershift experiments with antibodies specific for NFATc1, NFATc2, and NFATc3. Supershift or disappearance of the NFAT-DNA complex could be detected by incubation of nuclear extracts with antibodies against NFATc2 and NFATc1, but not NFATc3 ( Figure 4D ). Because transcription factor AP-1 can associate with NFAT under certain conditions, 28 we also included a c-Jun antibody in the supershift analyses. Interestingly, the c-Jun antibody did not reduce or supershift the NFAT-DNA complex, suggesting that AP-1 was not coupled to NFAT at the 2 sites of c-FLIP promoter ( Figure 4D ). Furthermore, we prepared nuclear extracts from freshly isolated, primary human T lymphocytes which also demonstrated an activation-dependent and CsA-inhibitable NFAT binding to site 1 and site 2 ( Figure 4E,F) .
To analyze the transcriptional activation of the human c-FLIP promoter by NFAT, luciferase assays were performed using a c-FLIP reporter construct (pGL3-FLIP) comprising the For personal use only. on January 21, 2018. by guest www.bloodjournal.org From promoter region 1 with both NFAT-binding sites ( Figure 5A ). For this purpose, we transiently expressed NFATc1 or NFATc2 together with a constitutively active form of calcineurin. Calcineurin was cotransfected because NFAT transcription factors are readily phosphorylated and thereby inactivated upon expression. Indeed, overexpression of NFATc1 as well as of NFATc2 in 293T cells resulted in an increased luciferase activity ( Figure 5B ). Moreover, mutation of the proposed NFAT binding sites strongly reduced luciferase expression, indicating that induction of the c-FLIP promoter by NFAT was indeed regulated by the suggested binding sites ( Figure 5B ). Next, we tested direct binding of NFAT transcription factors to the endogenous c-FLIP promoter by chromatin immunoprecipitation (ChIP). A stimulation-dependent binding of NFATc1 and NFATc2 to the first binding site was observed in CEM cells, confirming that c-FLIP was indeed a direct transcriptional target of NFAT ( Figure 5C ). Unfortunately, we were unable to analyze site 2 by ChIP, most likely because the surrounding A-T-rich sequences prevented an efficient PCR amplification. Nevertheless, these experiments clearly show that c-FLIP is a bona fide NFAT target gene.
FLIP proteins are strongly up-regulated in activated T cells and inhibit apoptosis by preventing the cleavage of initiator caspases in the DISC. To further determine the importance of the c-FLIP isoforms, we treated the human T-cell lines HuT78 and CEM with the CD95L to trigger the extrinsic apoptosis cascade. Both cell lines were highly apoptosis-sensitive, as detected by a CD95L-induced increase of DNA fragmentation ( Figure 6 ). CEM cells, like HuT78 cells, strongly up-regulated FLIP proteins upon activation, which was blocked by the addition of CsA ( Figure S2A ). Accordingly, T-cell activation led to a protection of both cell lines against CD95-mediated apoptosis, whereas CsA treatment inhibited c-FLIP up-regulation and rendered the cells sensitive again (Figure 6 ).
In order to delineate the relative contributions of the short and long isoforms to this protection, we next used RNA interference and stably infected CEM cells with lentiviral shRNA constructs targeting c-FLIP long , c-FLIP short , or both isoforms ( Figure 7A ). The knock-down of c-FLIP long was less efficient than that of c-FLIP short , which may be explained by the different half-life of the 2 proteins. 7,29 Activation of CEM cells by PMA/ionomycin induced an up-regulation of CD95L and a certain degree of apoptosis, which was almost completely prevented by a neutralizing CD95L antibody ( Figure 7B c-FLIP SHORT Figure 7C ). Cells expressing shRNAs against both c-FLIP isoforms were highly sensitive to apoptosis and significantly more susceptible than isoform-specific knock-down cells. Of note, while both single knock-down cells showed a similar apoptosis sensitivity upon addition of CD95L, c-FLIP short single knock-down cells displayed a higher overall apoptosis rate due to the increased level of activation-induced apoptosis ( Figure 7D ).
To analyze whether c-FLIP is the major antiapoptotic target of the calcineurin/NFAT pathway, we tested whether CsA can still sensitize the different knock-down cell lines. CsA sensitized control shRNAexpressing cells toward apoptosis, whereas cells in which c-FLIP short or both isoforms were knocked down showed only a marginal PMA/ ionomycin-mediated protection against apoptosis and a strongly reduced sensitization by CsA ( Figure 7D ). Interestingly, c-FLIP long single knock-down cells were still markedly sensitized by CsA, which was most likely due to the CsA-induced inhibition of c-FLIP short expression. Altogether, these data suggest that c-FLIP plays a central role in the protection against CD95-mediated apoptosis upon T-cell activation. Furthermore, apoptosis inhibition in activated T cells appears to be predominantly regulated by the short rather than the long c-FLIP isoform.
Discussion
Previous reports have shown that c-FLIP and particularly the truncated isoform c-FLIP short is up-regulated upon T-cell activation. 7, 9, 14, 30, 31 The signaling mechanisms leading to c-FLIP gene induction in short-term activated T cells, however, have not directly been investigated. We show here by various means including pharmacologic inhibition, reporter gene assays as well as EMSA and ChIP analyses, that c-FLIP is a bona fide NFAT target gene in T cells. Moreover, we demonstrate that induction of c-FLIP in recently activated T cells is important to prevent activation-induced suicide mediated by a concomitant up-regulation of the CD95L. In this context, it is important to note that treatment with CsA almost exclusively affected c-FLIP short expression and that CsA-treated T cells were as sensitive toward CD95L as T cells with a knock-down of both c-FLIP isoforms. Moreover, isoform-specific knock-down of c-FLIP splice variants revealed that particularly c-FLIP short -deficient cells were sensitive toward activation-induced apoptosis. Therefore, c-FLIP short rather than c-FLIP long may be a crucial factor determining the resistance of recently activated T cells. Transcription of the c-FLIP gene has been shown to be induced by NF-B 15, 16 and the androgen receptor 32 and to be repressed by c-Myc, 21 E2F1, 33 FOXO3a, 34 and AP-1. 35 Interestingly, p53 had opposite effects on c-FLIP expression in different cellular systems, as one report showed induction and another study repression of c-FLIP by p53. 36, 37 Given this context-specific regulation of c-FLIP expression by p53, it is conceivable that distinct transcription factors are involved in c-FLIP expression in different cell types. As most of the previous studies have been performed in nonhematopoietic cell lines, we therefore wished to analyze signaling pathways involved in the regulation of the c-FLIP gene in T cells. We demonstrate that in primary T cells and in T-cell lines, the calcineurin/NFAT pathway is particularly important for c-FLIP short transcription. Interestingly, NFATc1/A, an inducible isoform with a truncated C-terminal domain, is strongly up-regulated in activated T cells by an NFAT-dependent autoregulatory loop. 38 In contrast to other NFAT proteins, NFATc1/A is unable to promote anti-CD3-induced apoptosis. It is therefore assumed that different NFAT isoforms have distinct target gene preferences and differentially regulate pro-and antiapoptotic genes in effector T cells. As we found a role for both NFATc1 and NFATc2 in c-FLIP promoter activity, it is thus tempting to speculate that NFATc1/A or threshold levels of individual NFAT proteins control c-FLIP short expression and thereby regulate T-cell effector function.
In contrast to previous reports, 30, 39 we did not find any evidence that the MAPK or PI3K/Akt pathways were essential for expression of c-FLIP in T cells. This may be explained by differences in the experimental systems, as we analyzed protein instead of RNA expression and investigated primary human T cells instead of transformed cell lines. Although no direct binding to the promoter has been shown, c-FLIP is generally considered an NF-B target gene. This view is supported by the finding that activators of NF-B (including TNF␣, LPS, or anti-CD40) induce c-FLIP expression, whereas cells deficient in NF-B activation show reduced c-FLIP induction. [15] [16] [17] Accordingly, high expression of c-FLIP is generally observed in chronic inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and Behçet disease. 18, [40] [41] [42] It was, however, also reported that NF-B RelA-deficient mouse embryonic fibroblasts do not differ in tumor necrosis factor (TNF)-induced c-FLIP expression compared with wild-type cells, suggesting that c-FLIP expression can occur independently of NF-B. 43 In contrast to CsA, we found that rocaglamide, which has been shown to inhibit NF-B as well as NFAT transcription factors, 25, 26 impaired the expression of both c-FLIP long and c-FLIP short , suggesting that NF-B indeed contributes to c-FLIP gene regulation in T cells. It is therefore conceivable that NF-B acts as a general activator of the c-FLIP gene during T-cell activation, whereas the calcineurin/NFAT pathway might more specifically enhance expression the c-FLIP short isoform. Thus, our data demonstrate for the first time that a particular c-FLIP splice variant is induced by a certain transcription factor. Whether NFAT is involved in a transcription-coupled splicing event is an intriguing possibility that should be investigated in future studies.
Upon encounter with pathogens, T cells become activated and initiate effector mechanisms, one of which is the killing of infected target cells by CD95L. 44 Surprisingly, although recently activated T cells highly up-regulate CD95 receptor 1,7 as well as its ligand, 45-47 they do not commit suicide or induce fratricide in the initial immune response. Therefore, T cells must have various cell-survival mechanisms to prevent their elimination during activation. One of these is the up-regulation of antiapoptotic proteins such as Bcl-x L upon T-cell activation (Figure 1 ). 14,48 Moreover, we have previously shown that short-term activated T cells have a reduced capacity for DISC formation. 2, 14 Here we demonstrate that in primary human T cells c-FLIP short is highly up-regulated at the mRNA and protein level, while expression of c-FLIP long is only marginally modulated. The induction of c-FLIP, especially the c-FLIP short isoform, in recently activated T cells plays an important functional role in protection from CD95-mediated apoptosis, as an RNAi-mediated knock-down of c-FLIP sensitized T cells for CD95L-induced as well as activation-induced apoptosis. Strikingly, the cells, especially those in which c-FLIP short had been knocked down, displayed a highly elevated sensitivity toward activation-induced apoptosis. Therefore, c-FLIP short is an important mediator of resistance acquired by an activated T cell to protect itself from death receptor-mediated apoptosis.
CsA and FK506 are immunosuppressive drugs commonly used in transplantation medicine to induce immunologic tolerance. Sensitization to CD95-mediated apoptosis may contribute to the tolerance-promoting effects of these drugs. Supporting this hypothesis is a study showing that CsA sensitized CD28-costimulated rat T cells toward CD95-mediated apoptosis by up-regulating caspase-3 expression. 49 We observed impaired c-FLIP short expression in CsA-treated activated T cells, providing an alternative molecular mechanism for tolerance induction by regulating apoptosis sensitivity. Interestingly, accumulating evidence suggests that calcineurin and NFAT transcription factors not only play an essential role in development and the immune system, but also in tumor development. 50, 51 Moreover, c-FLIP is highly expressed in certain tumors, suggesting it as a potential therapeutic target. 52 In line with these observations, NFAT and c-FLIP were shown to support angiogenesis, 53 an essential process for tumor growth. In addition, it was recently demonstrated that inhibition of calcineurin by CsA or FK506 in vivo led to clearance of malignant cells and a better survival in 2 mouse models of leukemia. 54 Nevertheless, due to the various functions of calcineurin, long-term treatment with CsA is associated with severe side effects. Thus, direct interference with the expression of NFAT target genes could be an alternative strategy for immunosuppression. Our data suggest that c-FLIP might be such a target gene involved in tumorigenesis and immunosuppression.
